

**Table 1** Preoperative characteristics of patients with or without preoperative chemotherapy

<b>Preoperative factor</b>	<b>Preoperative chemotherapy Group (n=15)</b>	<b>No chemotherapy Group (n=12)</b>	<b>p value</b>
Age : Median (ranges)	65 (53-81)	56 (39-79)	0.038
Sex (M/F)	10/5	7/5	0.953
BMI (kg/m <sup>2</sup> )	24.1 ± 3.6	23.5 ± 2.4	0.616
WBC(/ $\mu$ l)	4640 ± 1861	5725 ± 1099	0.087
Hb(g/dL)	11.9 ± 1.8	12.2 ± 1.7	0.674
Plt (/ $\mu$ l)	18.3± 4.6	26.8 ± 10.8	0.011
Prothrombin time(%)	101.5 ± 11	109.2 ± 7.7	0.056
Albumin(g/dl)	3.8 ± 0.4	4.1 ± 0.3	0.012
Serum bilirubin (mg/dl)	0.7 ± 0.3	0.6 ± 0.2	0.661
AST(U/L)	26.4 ± 8.5	25.4 ± 16	0.684
ALT(U/L)	25.9 ± 12	25.3 ± 16	0.912
Pre-operative ICG R15(%)	14.4 ± 6.3	6.8 ± 3.2	0.001
Asialo scintigraphy (LHL15)	0.933 ± 0.25	0.926 ± 0.31	0.034
Cycles of FOLFOX	7.7 ± 2.1	—	
Duration of FOLFOX(months)	4.1 ± 1.2	—	
Days after last FOLFOX(days)	37 ± 20 (median 30)	—	

BMI indicates body mass index.

Values are mean ±SD.

Table 2 Pre-operative characteristics of liver metastases with or without preoperative chemotherapy

	<b>Preoperative chemotherapy Group(n=15)</b>	<b>No chemotherapy Group(n=12)</b>	<b>p value</b>
Tumor size (mm)	$34.6 \pm 17$	$66.7 \pm 43$	0.013
Number of metastasis	$5.9 \pm 5.6$	$2.4 \pm 2.2$	0.054
Primary site, Colon/Rectum	10 / 5	7 / 5	0.952
Synchronous/ Metachronous	11 / 4	3 / 9	0.03
CEA : Mean (range)	206.6 (1.2-2428)	285.4 (1.1-3157)	0.791

Values are mean  $\pm$ SD.

Table 3 Intra-operative parameters of patients with or without preoperative chemotherapy

	<b>Preoperative chemotherapy Group(n=15)</b>	<b>No chemotherapy Group(n=12)</b>	<b>p value</b>
Resection type			
hemi liver / section / partial	3 / 7 /5	5 / 2 /5	0.210
Vascular interruption time (min)			
total	21.0 ± 31	30.0 ± 33	0.453
partial	58.9 ± 70	24.0 ± 60	0.185
Blood loss(mean ±SD)(ml)	435 ± 247	383 ± 458	0.714
No. of patients requiring blood transfusion(%)	15.4%	10.0%	0.999
Operative time (min)	501 ± 92	448 ±180	0.323

Values are mean ±SD.

Table 4 Pathologic features of the non-tumorous liver in patients with or without chemotherapy

	<b>Preoperative chemotherapy Group (n=15)</b>	<b>No chemotherapy Group (n=12)</b>	<b>p value</b>
Macroscopic findings			
<u>Blue liver (positive/negative)</u>	7/8	0/12	0.020
Microscopic findings			
Steatosis ; grade 0/1/2/3	9/6/0/0	8/2/2/0	0.768
NAFLD Activity Score (NAS) 0~2/3~4/ 5	9/6/0	10/0/2	0.302
Sinusoidal Dilatation;Rubbia- Brandt Classification 0/1/2/3	3/8/4/1	6/5/1/0	0.056
Hemorrhagic centrilobular necrosis	0	0	
Regenerative nodular hyperplasia	0	0	

Values are mean ±SD.

Table 5 Postoperative liver function in patients with or without chemotherapy

	<b>Preoperative chemotherapy Group (n=15)</b>	<b>No chemotherapy Group (n=12)</b>	<b>p value</b>
post-operative value (mean $\pm$ SD)			
Prothrombin time(%)	64 $\pm$ 12	72 $\pm$ 16	0.158
Albumin(g/dl)	3.0 $\pm$ 0.4	3.2 $\pm$ 0.4	0.297
Total bilirubin (mg/dl)	1.4 $\pm$ 0.7	1.6 $\pm$ 0.8	0.505
AST(U/L)	798 $\pm$ 400	535 $\pm$ 405	0.105
ALT(U/L)	644 $\pm$ 403	509 $\pm$ 365	0.370

Values are mean  $\pm$ SD.

\* the worst value of postoperative hospital stay

Table 6 Postoperative morbidity and mortality in patients with or without chemotherapy

	<b>Preoperative chemotherapy Group (n=15)</b>	<b>No chemotherapy Group (n=12)</b>	<b>p value</b>
postoperative events (%)			
Any complications	2 (13%)	3 (25%)	0.770
	aspiration pneumonia (1)	hemorrhage (1)	
	bile leakage (1)	bile leakage (2)	
Reoperation	0 (0%)	0 (0%)	
Postoperative hospital stay (mean $\pm$ SD)(days)	26 $\pm$ 28	18 $\pm$ 12	0.300
Postoperative mortality	0 (0%)	0 (0%)	

Values are mean  $\pm$ SD.